Back to Blogs
Health Awareness Dr. Md. Nadeem Parvez (MD, DM – PGIMER Chandigarh, Head of Department, Gastroenterology) June 11, 2026

Act Now. Screen Early. Protect Your Liver: Global Fatty Liver Day 2026

Global Fatty Liver Day 2026, observed on 11 June, focuses on the theme "Act Now. Screen Early. Protect Your Liver." This guide explains what MASLD is, who is at risk, why early screening matters, and what practical lifestyle steps can protect liver health.

Act Now. Screen Early. Protect Your Liver: Global Fatty Liver Day 2026

Introduction

Global Fatty Liver Day 2026 is observed on 11 June and aims to shine a spotlight on the growing problem of fatty liver disease around the world. The campaign theme for this year, "Act Now. Screen Early. Protect Your Liver," highlights the urgent need for early detection, timely lifestyle changes, and preventive healthcare. 1234

Fatty liver disease is now one of the most common liver conditions globally, affecting roughly one in three adults, and its numbers are rising in parallel with obesity and type 2 diabetes. Many people have fatty liver without knowing it, which is why awareness and simple screening tests are so important.

What is Fatty Liver Disease?

Fatty liver disease means extra fat has built up in the liver cells, usually more than 5% of the liver's weight. When this fat accumulation happens in people who drink little or no alcohol and have metabolic risk factors such as obesity, diabetes, or high blood pressure, it is now called Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). 3

MASLD is the new name for what was previously known as non-alcoholic fatty liver disease (NAFLD); the more severe inflammatory form once called NASH is now termed Metabolic Dysfunction-Associated Steatohepatitis (MASH). This updated terminology emphasizes that metabolic problems — not alcohol — are the main drivers of this condition. 5

MASLD includes a spectrum of liver conditions:

  • Simple fatty liver (fat accumulation without major inflammation)
  • Metabolic dysfunction-associated steatohepatitis (MASH), a more severe form with liver inflammation
  • Liver fibrosis (scarring)
  • Cirrhosis
  • Liver cancer

Why Should We Be Concerned?

Recent global studies show that around 30% of the world's adult population has fatty liver disease, and the numbers have risen by more than 50% over the last three decades. New estimates suggest that over a billion people are living with MASLD, and this number is projected to increase further if current trends in obesity and diabetes continue. 267

MASLD is closely linked with obesity, type 2 diabetes, high blood pressure, abnormal cholesterol, and metabolic syndrome — conditions that are themselves extremely common. Importantly, people with MASLD have a higher risk of heart attacks, strokes, and other cardiovascular problems, and cardiovascular disease is now recognized as a leading cause of death in this group.

Why is Fatty Liver Called a Silent Disease?

In the early stages, fatty liver disease usually causes no obvious symptoms, which is why it is often called a "silent" condition. Many people feel well and only discover they have fatty liver when routine blood tests show mildly abnormal liver enzymes or when an ultrasound scan done for another reason shows a "bright" or fatty liver. 839

Because symptoms are so subtle, a large proportion of people with MASLD remain undiagnosed until the disease has progressed or until they develop complications such as cirrhosis, liver cancer, or cardiovascular events. This makes proactive screening in people at high risk extremely important.

Who is at Risk?

You may be at higher risk of MASLD if you have one or more of the following: 10

  • Overweight or obesity, especially increased waist size or central (tummy) fat
  • Type 2 diabetes or prediabetes
  • High cholesterol or high triglycerides
  • High blood pressure (hypertension)
  • Sedentary lifestyle, with little physical activity
  • Family history of fatty liver disease, cirrhosis, or liver cancer
  • Polycystic Ovary Syndrome (PCOS) in women, which is associated with a higher prevalence of fatty liver due to shared hormonal and metabolic abnormalities

Warning Signs and Symptoms

Most people with fatty liver disease have no symptoms during the early stages. 11

When symptoms do occur, they may include:

  • Persistent fatigue
  • Feeling tired or weak
  • Mild discomfort or heaviness in the upper right side of the abdomen
  • Unexplained elevation of liver enzymes during blood tests

In advanced disease, symptoms may become more serious and include:

  • Swelling of the abdomen
  • Yellowing of the eyes or skin (jaundice)
  • Leg swelling
  • Easy bruising

These signs may indicate advanced liver damage and require urgent medical attention.

Why Screening Matters?

Early detection can help prevent serious liver complications. Screening allows doctors to identify liver disease before irreversible damage occurs. 121314

Healthcare professionals now recommend screening high-risk individuals, especially those with:

  • Type 2 diabetes
  • Obesity
  • Metabolic syndrome
  • Hypertension
  • High cholesterol

One commonly used assessment tool is the FIB-4 score, a simple calculation based on age and routine blood test results. It helps doctors estimate the risk of liver scarring without invasive procedures.

Other non-invasive methods include:

  • Liver ultrasound
  • FibroScan (liver stiffness measurement)
  • Blood-based fibrosis tests

These tests are painless and can help identify patients who need further evaluation or specialist care. The message of Global Fatty Liver Day 2026 is therefore extremely important: "Act Now. Screen Early. Protect Your Liver."

Possible Complications if Left Untreated

If fatty liver disease progresses untreated, it can lead to serious health complications. 315 These may include:

  • MASH (Metabolic Dysfunction-Associated Steatohepatitis): A more aggressive form where fat, inflammation, and liver cell injury coexist
  • Liver Fibrosis: Persistent inflammation can cause scarring of the liver tissue
  • Cirrhosis: Advanced scarring may permanently damage liver function
  • Liver Cancer: Patients with advanced MASLD are at increased risk of hepatocellular carcinoma (liver cancer)
  • Cardiovascular Disease: Heart disease remains the most common cause of death in patients with MASLD
  • Liver Transplantation: MASLD has become one of the leading reasons for liver transplantation in many countries

Protecting Your Liver: What You Can Do Today!

The encouraging news is that lifestyle modification can significantly improve fatty liver disease, especially in the early stages. 161718

Practical steps to protect your liver include:

  • Maintain a Healthy Weight: Even a 5–7% weight loss improves liver fat, and around 7–10% weight loss has been linked with resolution of NASH/MASH and regression of fibrosis in many patients.
  • Eat a Balanced Diet:
    Choose: fruits and vegetables, whole grains, lean proteins, healthy fats.
    Reduce: sugary drinks, processed foods, excess fried foods, excessive salt intake.
  • Stay Physically Active: Aim for at least 150–300 minutes of moderate-intensity exercise per week, such as brisk walking, cycling, or swimming, plus muscle-strengthening activities twice weekly.
  • Control Blood Sugar: Good diabetes management helps reduce liver-related complications.
  • Manage Blood Pressure and Cholesterol: Proper control of metabolic risk factors protects both the liver and heart.
  • Avoid Alcohol: Even though MASLD is not caused by alcohol, excess drinking can accelerate liver damage; your doctor can advise what is safe for you.
  • Do not rely on unproven "liver cleansers": Many herbal or over-the-counter products are untested and may actually harm the liver; always discuss supplements with your doctor.
  • Schedule Regular Health Checkups: Routine screening helps identify problems early.

Call to Action for Global Fatty Liver Day 2026

Global Fatty Liver Day 2026 is an opportunity for individuals, families, communities, and health systems to make liver health a priority. If you recognize any of the risk factors described above, talk to your healthcare professional about getting screened even if you feel completely well.

Hospitals, clinics, and health organizations can use this day to run screening camps, public talks and educational campaigns that highlight simple tools like FIB-4 and liver stiffness scans for early risk assessment. By promoting healthy lifestyle habits and timely screening, we can reduce the burden of liver disease and cardiovascular complications in our communities.

Conclusion

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a major, yet largely silent, global health threat. Because the condition is often asymptomatic in its early stages, routine screening of high-risk populations using non-invasive tools like the FIB-4 index is essential to catching progressive liver damage early. With lifestyle modifications, optimal management of metabolic comorbidities, and new targeted medical therapies, individuals can successfully protect and improve their liver health.

On Global Fatty Liver Day 2026, take a moment to think about your liver: know your risk, ask about screening, and commit to healthier daily habits for you and your family. Act Now. Screen Early. Protect Your Liver.

Key Take-Home Messages

  • Fatty liver disease (MASLD) is extremely common worldwide and is closely linked with obesity, type 2 diabetes and other metabolic problems.
  • Most people with MASLD have no symptoms, so many remain undiagnosed until late stages or complications occur.
  • Cardiovascular disease — not just liver failure — is a major cause of illness and death in people with MASLD.
  • High-risk groups include those who are overweight, have type 2 diabetes, high blood pressure, abnormal cholesterol, sedentary lifestyle, family history of liver disease or PCOS in women.
  • Simple tools like the FIB-4 score, calculated from routine blood tests and age, help identify who may have advanced liver scarring and who can be safely monitored in primary care.
  • Weight loss of about 7–10%, a Mediterranean-style diet, regular physical activity and good control of blood sugar, blood pressure and cholesterol can significantly improve liver health.
  • On Global Fatty Liver Day 2026, remember the message: "Act Now. Screen Early. Protect Your Liver."

References

  1. Clémence M Canivet et al. Semin Liver Dis. 2024 Feb;44(1):35-42.
  2. Kim S, Oh J, Shin J et al. The Lancet Gastroenterology & Hepatology, 2026; 11, 463-494.
  3. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts. 2024;17(4):374-444.
  4. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-1347.
  5. Girish V, John S. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [Updated 2025 Aug 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541033/
  6. Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik JM. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024 Oct;22(10):1999-2010.e8.
  7. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-1347.
  8. Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021 Jul;110(7):921-937.
  9. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014 Jul 29;349:g4596.
  10. Shengir M, Chen T, Guadagno E, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis. JGH Open. 2021 Feb 25;5(4):434-445.
  11. Lazarus JV, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index. Nat Med. 2022;28(11):2236-45.
  12. Kanwal F, Shubrook JH, Younossi Z, et al. Preparing for the NASH epidemic. Diabetes Care. 2021;44(1):216-25.
  13. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1).
  14. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients. Hepatology. 2006;43(6):1317-25.
  15. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC. J Hepatol. 2021;75(5):1204-16.
  16. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of NASH. Gastroenterology. 2015;149(2):367-78.
  17. Mediterranean diet and nonalcoholic fatty liver disease: Clinical evidence and mechanisms. World J Gastroenterol. 2022;28(30):4040-55.
  18. Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in NAFLD safe? Hepatology. 2017;65(6):2090-99.

This educational content is authored by Dr. Md. Nadeem Parvez (MD, DM – PGIMER Chandigarh, Head of Department, Gastroenterology), and is intended for patient awareness and public health education. For personalized consultation and liver care, please consult with a qualified gastroenterologist or hepatologist.